Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Forecasted Market Size Estimates For The Human Immunodeficiency Virus Therapeutics Market Between 2025 And 2029?
The human immunodeficiency virus therapeutics market size has shown strong expansion in recent years. It is anticipated to increase from $14.11 billion in 2024 to $14.9 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.6%. This historical growth can be linked to factors such as an uptick in HIV prevalence, more robust awareness programs, an increase in diagnostic testing, greater generic drug penetration, and enhancements in healthcare infrastructure.
The human immunodeficiency virus therapeutics market size is anticipated to undergo significant expansion in the coming years, with projections indicating a growth to $18.44 billion by 2029, driven by a compound annual growth rate (CAGR) of 5.5%. This forecasted growth can be linked to an increasing pool of HIV patients, enhanced HIV screening procedures, a rise in voluntary testing, an escalation in unprotected sexual practices, and the expansion of government-sponsored programs. Key trends expected to shape the market during this period include continuous technological advancements, the utilization of AI for drug discovery, the development of long-acting injectable therapies, the integration of telemedicine services, and the progression of CRISPR-based gene therapy.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23419&type=smp
Which Industry Drivers Are Expected To Accelerate The Human Immunodeficiency Virus Therapeutics Market From 2025 To 2029?
The increasing incidence of unprotected sexual activities is projected to stimulate the expansion of the human immunodeficiency virus therapeutics market in the future. These practices involve sexual encounters lacking barrier protection, consequently elevating the danger of sexually transmitted infections (STIs) and unplanned pregnancies. A deficiency in thorough sex education contributes to inadequate understanding of safe behaviors, thereby fostering risky conduct among younger individuals. Human immunodeficiency virus therapeutics play a crucial role in lowering the likelihood of HIV transmission stemming from unprotected sexual acts by achieving undetectable viral loads, thereby halting the further dissemination of the infection. An illustrative example comes from November 2024, where data from the Centers for Disease Control and Prevention, a US-based government agency, revealed that a 2023 survey of U.S. high school students indicated 32% had engaged in sexual intercourse at least once, and 48% admitted to not using a condom during their most recent sexual encounter. Consequently, the rising occurrence of unprotected sexual practices is a significant factor propelling the expansion of the human immunodeficiency virus therapeutics market.
What Are The Major Segment Types Covered In The Human Immunodeficiency Virus Therapeutics Market?
The human immunodeficiency virus therapeuticsmarket covered in this report is segmented –
1) By Drug Type: Branded Drugs; Generic Drugs
2) By Drug Class: Nucleoside-Analog Reverse Transcriptase Inhibitors (Nrtis); Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis); Entry And Fusion Inhibitors; Protease Inhibitors (Pis); Integrase Inhibitors; Coreceptor Antagonists
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
4) By End-user: Hospitals And Clinics; Specialty Centers
Subsegments:
1) By Branded Drugs: Biktarvy; Triumeq; Genvoya; Juluca; Dovato; Isentress; Prezista
2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF); Lamivudine; Efavirenz; Zidovudine; Nevirapine; Abacavir; Ritonavir
What Trends Are Expected To Drive The Human Immunodeficiency Virus Therapeutics Market?
Leading companies in the human immunodeficiency virus (HIV) therapeutics market are concentrating on developing innovative treatments, such as combination therapy, to enhance treatment efficacy, reduce drug resistance, and improve patient adherence. Combination therapy involves using two or more therapeutic agents, including drugs or other treatments, to manage a single disease or condition. This strategy boosts treatment effectiveness, minimizes side effects, and lowers the risk of drug resistance. For instance, in December 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for Sunlenca (lenacapavir). This treatment is intended for adults with multi-drug-resistant HIV-1, to be used in conjunction with other antiretroviral medications. Sunlenca is significant as the first and only HIV treatment founded on a capsid inhibitor, offering a convenient twice-a-year dosing option for patients who have undergone extensive prior treatment. The CAPELLA trial, which demonstrated high rates of sustained virologic suppression, provided the basis for this approval. With its novel mechanism of action and long-acting formulation, Sunlenca is projected to be a vital element in future HIV treatment and prevention strategies.
Which Leading Companies Dominate The Human Immunodeficiency Virus Therapeutics Market Share?
Major companies operating in the human immunodeficiency virus therapeutics market are Pfizer Inc., Johnson & Johnson, F Hoffmann La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol Myers Squibb Company (BMS), Novartis International AG, GlaxoSmithKline plc (GSK), Gilead Sciences Inc., Moderna Inc., BioNTech SE, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Cipla Limited, Hetero Labs Limited, Gilead Sciences Inc. / Kite Pharma Inc. (for CAR T HIV cure research), Vir Biotechnology Inc., Theratechnologies Inc., CytoDyn Inc.
Download The Full Report For Exclusive Market Findings:
Which Global Regions Are Influencing The Competitive Landscape Of The Human Immunodeficiency Virus Therapeutics Market?
North America was the largest region in the human immunodeficiency virus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency virus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Human Immunodeficiency Virus Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=23419&type=smp
Browse Through More Reports Similar to the Global Human Immunodeficiency Virus Therapeutics Market 2025, By The Business Research Company
Antivirus Software Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antivirus-software-global-market-report
Coronavirus Covid 19 Current Therapy Market 2025
https://www.thebusinessresearchcompany.com/report/coronavirus-covid-19-current-therapy-market
Virus Filtration Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/virus-filtration-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model